
THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of Formula (I)



(I),

or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, wherein:

X	is N or C-R^3,
Y	is N, NH or is absent,
R^1	is L^1–R^4–L^2–R^5-L^3-R^6 or L^1–R^4–L^2–R^5,
R^2	is A, Hal, OH, OA, SH, CN, NH_2, NO_2, NHA, NH–L^1–Ar, NHCOA, NHCO–L^1–Ar, $NHSO_2A$, $NHSO_2$–L^1–Ar, NHCONHA, NHCONH–L^1–Ar, L^1–Ar, O- L^1–Ar, L^1–R^4 or H,
L^1-L^3	each, independently of one another is a single bond, methylene, or methyl substituted methylene, wherein the methylene, or the methyl group of the methyl substituted methylene may be unsubstituted or mono- or disubstituted with Hal, OH, CN, NH_2,NH(LA), $N(LA)_2$, NO_2, COOH, N_3, ethenyl or ethynyl, and/or monosubstituted with R^4, and in which one or two CH_2 groups may be replaced by an O or S atom or by an –NH-, -N(LA)-, -CONH-, -N(LA)COO-, -SO_2- or -NHCO- group,
R^3	is H, A, Hal, OH, COOH, SH, NH_2, NO_2 or CN,
R^4	each, independently of one another, are cyclic A which may be mono-or disubstituted by Hal, or LA,

	R^5, R^6	each, independently of one another, are Ar, or cyclic A which may be mono- or disubstituted by Hal or LA,
	L^2	is –NHCO–, -NHCOO-, –NHCONH–, –NHCONA–, –NHCOA–, –O–, –S–, –NH–, –$NHSO_2$–, –SO_2NH–, –CONH–, –CONHCONH–, –NHCONHCO–, or –A-,
	Ar	is a mono- or bicyclic aromatic homo- or heterocycle having 0, 1, 2, 3 or 4 N, O and/or S atoms and 5, 6, 7, 8, 9, or 10 skeleton atoms, which may be unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, A, OH, SH, OA, NH_2, NHA, NA_2, NO_2, CN, OCN, SCN, COOH, COOA, $CONH_2$, CONHA, $CONA_2$, NHCOA, NHCONHA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A and/or SO_2Hal, and in which a ring N-atom may be substituted by an O-atom to form an N-oxide group, and in which in the case of a bicyclic aromatic cycle on of the two rings may be partly saturated,
	A	is unbranched or branched linear or cyclic alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, in which one or two CH_2 groups may be replaced by an O or S atom and/or by an –NH-, -CO-, -NHCOO-, -NHCONH-. -N(LA)-, -CONH-,-NHCO- or –CH=CH– group, and in which 1-3 H atoms may be replaced by Hal, and in which one or two CH_3 groups may be replaced by OH, SH, NH_2, NH(LA), $N(LA)_2$, NHCOOH, $NHCONH_2$ or CN,
	LA	is unbranched or branched, linear alkyl having 1, 2, 3 or 4 C atoms, wherein 1, 2 or 3 H atoms may be replaced by Hal and
	Hal	is F, Cl, Br or I.

2. A compound according to Claim 1 or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, wherein

X	is N,
Y	is NH,

R^1 is L^1–R^4–L^2–R^5,

R^2 is LA, Hal, OH, O(LA), SH, CN, NH_2, NO_2, NH(LA), NHCO(LA), $NHSO_2$(LA), NHCONH(LA) or H,

L^1 is methyl substituted methylene, wherein the methyl group of the methyl substituted methylene is monosubstituted with NH_2 or NH(LA), $N(LA)_2$, or cyclic A which may be mono- or disubstituted by Hal or LA,

R^4 each, independently of one another, are cyclic A which may be mono-or disubstituted by Hal, or LA,

R^5 is a monocyclic aromatic homo- or heterocycle having 0, 1 or 2 N, O and/or S atoms and 5 or 6 skeleton atoms, which may be unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, A, OH, SH, OA, NH_2, NHA, NA_2, NO_2, CN, OCN, SCN, COOH, COOA, $CONH_2$, CONHA, $CONA_2$, NHCOA, NHCONHA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A and/or SO_2Hal,


A is unbranched or branched linear or cyclic alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, in which one or two CH_2 groups may be replaced by an O or S atom and/or by an –NH-, -CO-, -NHCOO-, -NHCONH-. -N(LA)-, -CONH-,-NHCO- or –CH=CH– group, and in which 1-3 H atoms may be replaced by Hal, and in which one or two CH_3 groups may be replaced by OH, SH, NH_2, NH(LA), $N(LA)_2$, NHCOOH, $NHCONH_2$ or CN,

L^2 is –NHCO–, -NHCOO-, –NHCONH–, –NHCONA–, –NHCOA–, –O–, –S–, –NH–, $–NHSO_2–$, $–SO_2NH–$, –CONH–, –CONHCONH–, –NHCONHCO–, or –A-,

LA is unbranched or branched, linear alkyl having 1, 2, 3 or 4 C atoms, wherein 1, 2 or 3 H atoms may be replaced by Hal and

Hal is F, Cl, Br or I.

3. The compound of Formula (II)



(II)

or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, wherein:

X		is N or C-R^3,
R^2		is A, Hal, OH, OA, SH, CN, NH_2, NO_2, NHA, NH–L^1–Ar, NHCOA, NHCO–L^1–Ar, $NHSO_2A$, $NHSO_2$–L^1–Ar, NHCONHA, NHCONH–L^1–Ar, L^1–Ar, O- L^1–Ar, L^1–R^4,
R^3		is H, A, Hal, OH, COOH, SH, NH_2, NO_2 or CN,
Y'		is CH_2 or NH such that when Y' is NH, Z is CH_2 (or absent) and when Y' is CH_2, Z is NH,
Z		is CH_2, NH or is absent such that when Z is CH_2 (or absent), Y' is NH and when Z is NH, Y' is CH_2,
Z'		Ar, alkyl, halogen, OR, NRR, CF_3, CN, OCF_3, SR, H (mono, di, or tri-substituted with any above combination),
R		is methyl,
A		is unbranched or branched linear or cyclic alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, in which one or two CH_2 groups may be replaced by an O or S atom and/or by an -NH-, -CO-, -NHCOO-, -NHCONH-, -N(LA)-, -CONH-,-NHCO- or –CH=CH– group, and in which 1-3 H atoms may be replaced by Hal, and in which one or two CH_3 groups may be replaced by OH, SH, NH_2, NH(LA), $N(LA)_2$, NHCOOH, $NHCONH_2$ or CN,
Hal		is F, Cl, Br or I,


L^1 is a single bond, methylene, or methyl substituted methylene, wherein the methylene, or the methyl group of the methyl substituted methylene may be unsubstituted or mono- or disubstituted with Hal, OH, CN, NH_2,NH(LA), $N(LA)_2$, NO_2, COOH, N_3, ethenyl or ethynyl, and/or monosubstituted with R^4, and in which one or two CH_2 groups may be replaced by an O or S atom or by an –NH-, -N(LA)-, -CONH-, -N(LA)COO-, $-SO_2-$ or -NHCO- group,

Ar is a mono- or bicyclic aromatic homo- or heterocycle having 0, 1, 2, 3 or 4 N, O and/or S atoms and 5, 6, 7, 8, 9, or 10 skeleton atoms, which may be unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, A, OH, SH, OA, NH_2, NHA, NA_2, NO_2, CN, OCN, SCN, COOH, COOA, $CONH_2$, CONHA, $CONA_2$, NHCOA, NHCONHA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A and/or SO_2Hal, and in which a ring N-atom may be substituted by an O-atom to form an N-oxide group, and in which in the case of a bicyclic aromatic cycle on of the two rings may be partly saturated,

R^4 each, independently of one another, are cyclic A which may be mono-or disubstituted by Hal, or LA, and

LA is unbranched or branched, linear alkyl having 1, 2, 3 or 4 C atoms, wherein 1, 2 or 3 H atoms may be replaced by Hal.

4. The compound of Formula (III)



(III)

or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, wherein:

X	is N or C-R^3,
R^2	is A, Hal, OH, OA, SH, CN, NH_2, NO_2, NHA, NH–L^1–Ar, NHCOA, NHCO–L^1–Ar, $NHSO_2A$, $NHSO_2$–L^1–Ar, NHCONHA, NHCONH–L^1–Ar, L^1–Ar, O- L^1–Ar, L^1–R^4,
R^3	is H, A, Hal, OH, COOH, SH, NH_2, NO_2 or CN,
Y'	is CH_2 or NH such that when Y' is NH, Z is CH_2 (or absent) and when Y' is CH_2, Z is NH,
Z	is CH_2, NH or is absent such that when Z is CH_2 (or absent), Y' is NH and when Z is NH, Y' is CH_2, and
Z'	Ar, alkyl, halogen, OR, NRR, CF_3, CN, OCF_3, SR, H (mono, di, or tri-substituted with any above combination),
R	is methyl,
A	is unbranched or branched linear or cyclic alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, in which one or two CH_2 groups may be replaced by an O or S atom and/or by an -NH-, -CO-, -NHCOO-, -NHCONH-, -N(LA)-, -CONH-,-NHCO- or –CH=CH– group, and in which 1-3 H atoms may be replaced by Hal, and in which one or two CH_3 groups may be replaced by OH, SH, NH_2, NH(LA), $N(LA)_2$, NHCOOH, $NHCONH_2$ or CN,
Hal	is F, Cl, Br or I,
L^1	is a single bond, methylene, or methyl substituted methylene, wherein the methylene, or the methyl group of the methyl substituted methylene may be unsubstituted or mono- or disubstituted with Hal, OH, CN, NH_2,NH(LA), $N(LA)_2$, NO_2, COOH, N_3, ethenyl or ethynyl, and/or monosubstituted with R^4, and in which one or two CH_2 groups may be replaced by an O or S atom or by an –NH-, -N(LA)-, -CONH-, -N(LA)COO-, $-SO_2$- or -NHCO- group,
Ar	is a mono- or bicyclic aromatic homo- or heterocycle having 0, 1, 2, 3 or 4 N, O and/or S atoms and 5, 6, 7, 8, 9, or 10 skeleton atoms, which may be unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, A, OH, SH, OA, NH_2, NHA, NA_2, NO_2, CN, OCN, SCN, COOH, COOA, $CONH_2$, CONHA, $CONA_2$, NHCOA, NHCONHA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A and/or SO_2Hal, and in which a ring N-atom may be substituted by an O-atom to form an N-oxide group, and in which in the case of a bicyclic aromatic cycle on of the two rings may be partly saturated,

R^4 each, independently of one another, are cyclic A which may be mono-or disubstituted by Hal, or LA, and

LA is unbranched or branched, linear alkyl having 1, 2, 3 or 4 C atoms, wherein 1, 2 or 3 H atoms may be replaced by Hal.

5. The compound according to Claim 1, wherein the compound is selected from the group consisting of:

trans racemic 4-((4-(3-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

trans racemic 4-((4-phenylpyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

4-((4-(2-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

4-((4-(4-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

4-((4-(4-methoxyphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

4-((4-(3-methoxyphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide,

4-((4-(2-methoxyphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

trans, racemic 4-((4-(3-chlorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

trans, racemic 4-((4-(2-chloro-6-fluorophenyl)pyrrolidin-3-yl)amino)-quinazoline-8-carboxamide;

trans, racemic 4-((4-(3-bromophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

trans, racemic 4-((4-(3-fluorophenyl)-1-methylpyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

trans, racemic 4-((-4-(naphthalen-2-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

trans, racemic 4-((4-(naphthalen-1-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

6-methyl-4-((4-phenylpyrrolidin-3-yl)amino)quinazoline-8-carboxamide,

2-methyl-4-((4-phenylpyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

4-((4-(4-fluorophenyl)pyrrolidin-3-yl)amino)-2-methylquinazoline-8-carboxamide;

4-((4-(4-methoxyphenyl)pyrrolidin-3-yl)amino)-2-methylquinazoline-8-carboxamide;

4-((4-(4-fluorophenyl)-1-methylpyrrolidin-3-yl)amino)quinoline-8-carboxamide;
4-((4-phenylpyrrolidin-3-yl)amino)quinoline-8-carboxamide;
4-((4-(3-fluorophenyl)pyrrolidin-3-yl)amino)quinoline-8-carboxamide;
4-((4-(2-fluorophenyl)pyrrolidin-3-yl)amino)quinoline-8-carboxamide;
4-((4-(2-methoxyphenyl)pyrrolidin-3-yl)amino)quinoline-8-carboxamide;
4-((4-(3-methoxyphenyl)pyrrolidin-3-yl)amino)quinoline-8-carboxamide;
4-((4-(4-methoxyphenyl)pyrrolidin-3-yl)amino)quinoline-8-carboxamide;
trans-4-(4-Phenylcarbamoyl-pyrrolidin-3-ylamino)-quinazoline-8-carboxylic acid amide;
trans, racemic 4-((4-phenylpiperidin-3-yl)amino)quinazoline-8-carboxamide;
racemic, trans 4-((4-(3-fluorophenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
cis, racemic 4-((4-phenylpiperidin-3-yl)amino)quinazoline-8-carboxamide;
trans, racemic 4-((4-(3-(trifluoromethyl)phenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
trans, racemic 4-((4-(m-tolyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
trans, racemic 4-((4-(4-fluorophenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
trans, racemic tert-butyl 3-amino-4-(4-chlorophenyl)piperidine-1-carboxylate;
racemic,
trans, Benzyl 3-amino-4-(3-fluoro-4-methylphenyl)piperidine-1-carboxylate;
trans, racemic Benzyl 3-((8-carbamoylquinazolin-4-yl)amino)-4-(3-fluoro-4-methylphenyl)piperidine-1-carboxylate;
racemic, trans 4-((4-(3-fluoro-4-methylphenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
trans, racemic 4-((4-(3-fluorophenyl)piperidin-3-yl)amino)-2-methylquinazoline-8-carboxamide;
trans, racemic 2-ethyl-4-((4-(3-fluorophenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
trans, racemic 2-ethyl-4-((4-phenylpiperidin-3-yl)amino)quinazoline-8-carboxamide;
trans, racemic 2-methyl-4-((4-phenylpiperidin-3-yl)amino)quinazoline-8-carboxamide;
trans, racemic 4-((4-phenylpiperidin-3-yl)amino)quinoline-8-carboxamide;
trans, racemic Ethyl 8-carbamoyl-4-(4-phenylpiperidin-3-yl)amino)quinoline-3-carboxylate;
trans, racemic 8-carbamoyl-4-((4-phenylpiperidin-3-yl)amino)quinoline-3-carboxylic acid;

4-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-fluoro-5-(trifluoromethyl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(3-fluoro-5-(trifluoromethyl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(3-fluoro-5-(trifluoromethyl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-(trifluoromethyl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(3-(trifluoromethyl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(3-(trifluoromethyl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-(trifluoromethyl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(4-(trifluoromethyl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(4-(trifluoromethyl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4R)-4-(4-(trifluoromethyl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(3-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4R)-4-(3-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(4-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(4-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(4-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(3-fluoro-4-methoxyphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(3-fluoro-4-methoxyphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(3-chlorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(2-chlorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

4-(((3S,4R)-4-(2-chlorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(3-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(3-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(quinolin-6-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(quinolin-6-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(quinolin-6-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(3-methoxyphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(3-methoxyphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(4-fluoro-3-methylphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(4-fluoro-3-methylphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(4-fluoro-3-methylphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(naphthalen-1-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(naphthalen-1-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(naphthalen-1-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(naphthalen-2-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(naphthalen-2-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-fluorophenyl)pyrrolidin-3-yl)amino)-2-methylquinazoline-8-carboxamide;
4-(((3R,4S)-4-(3-fluorophenyl)pyrrolidin-3-yl)amino)-2-methylquinazoline-8-carboxamide;
4-(((3S,4R)-4-(3-fluorophenyl)pyrrolidin-3-yl)amino)-2-methylquinazoline-8-carboxamide;
4-(3-bromophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-cyanophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(3-cyanophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(3-cyanophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(2,3-dihydrobenzofuran-5-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(2,3-dihydrobenzofuran-5-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(2,3-dihydrobenzofuran-5-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-fluoro-2-methylphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;

4-(((3R,4S)-4-(3-fluoro-2-methylphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(3-fluoro-2-methylphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(3-chlorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(4-methoxyphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(4-methoxyphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
2-chlorophenyl)pyrrolidin-3-yl)amino)-2-methylquinazoline-8-carboxamide;
4-(4-chloro-3-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-chloro-4-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(4-chloro-3-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-fluoro-4-methoxyphenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(4-chloro-3-fluorophenyl)pyrrolidin-3-yl)amino)-2-methylquinazoline-8-carboxamide;
2-ethyl-4-(((3S,4R)-4-(3-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
2-ethyl-4 -(3-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
2-ethyl-4-(((3R,4S)-4-(3-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-chloro-2-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(naphthalen-2-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(4-(methylsulfonyl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(4-chloro-3-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(4-chloro-3-fluorophenyl)pyrrolidin-3-yl)amino)-2-ethylquinazoline-8-carboxamide;
4-(3-chloro-5-fluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
6-fluoro-4-(((3R,4S)-4-(4-(trifluoromethyl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(2,3-difluorophenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4S)-4-(3-(pyrrolidin-1-yl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-([1,1'-biphenyl]-3-yl)pyrrolidin-3-yl)amino)quinazoline-8- carboxamide;

4-(4-fluoro-3-(pyridin-3-yl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(2-fluoro-[1,1'-biphenyl]-4-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-fluoro-4-(pyridin-3-yl)phenyl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
2-ethyl-4-((4-(trifluoromethyl)phenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3,5-difluorophenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
1-methyl-4-phenylpiperidin-3-yl)amino)quinazoline-8-carboxamide;
2-ethyl-4-(3-(trifluoromethyl)phenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-methoxyphenyl)piperidin-3-yl)amino)-2-methylquinazoline-8-carboxamide;
4-(4-(trifluoromethyl)phenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4S)-4-(4-(trifluoromethyl)phenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4R)-4-(4-(trifluoromethyl)phenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3R,4R)-4-(3-(trifluoromethyl)phenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4S)-4-(3-(trifluoromethyl)phenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-(4-fluorophenyl)piperidin-3-yl)amino)-2-methylquinazoline-8-carboxamide;
2-ethyl-4-(4-fluorophenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-(4-fluorophenyl)piperidin-3-yl)amino)-2-methylquinazoline-8-carboxamide;
4-(3-methoxyphenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-(2-fluorophenyl)piperidin-3-yl)amino)-2-methylquinazoline-8-carboxamide;
4-(3-fluoro-4-methylphenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
2-methyl-4-(((3R,4R)-4-(3-(trifluoromethyl)phenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3,4-dimethoxyphenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-(3-fluoro-5-(trifluoromethyl)phenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
2-methyl-4-(4-(trifluoromethyl)phenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
2-ethyl-4-(2-fluorophenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-(4-chlorophenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
2-ethyl-4-(m-tolyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
4-((4-(3,5-dimethylphenyl)piperidin-3-yl)amino)quinazoline-8-carboxamide;
6-fluoro-4-(((3R,4R)-4-phenylpiperidin-3-yl)amino)quinazoline-8-carboxamide;

4-(((3R,4S)-4-(2-fluoro-[1,1'-biphenyl]-4-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide;
4-(((3S,4R)-4-(2-fluoro-[1,1'-biphenyl]-4-yl)pyrrolidin-3-yl)amino)quinazoline-8-carboxamide
or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof.

6. A pharmaceutical composition comprising a compound according to any of claims 1 to 5, or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, as active ingredient, together with a pharmaceutically acceptable carrier.

7. A compound of any of claims 1 to 5, or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, or a pharmaceutical composition of claim 6, for use as a medicament.

8. A compound of any of claims 1 to 5, or a pharmaceutically acceptable salt, solvate, solvate, solvate of a salt, or prodrug thereof, or a pharmaceutical composition of claim 6, for treating hyperproliferative diseases.

9. The compound or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, or the pharmaceutical composition, of claim 8, wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma and Kaposi's sarcoma.

10. Use of a compound of any of claims 1 to 5, or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, or a

pharmaceutical composition of claim 6, for the preparation of a medicament for the treatment of hyperproliferative diseases.

11. Use of a compound of any of claims 1 to 5, or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, or a pharmaceutical composition of claim 6, for the treatment of hyperproliferative diseases.

12. Use according to claim 10 or 11, wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma and Kaposi's sarcoma.

13. A method for treating hyperproliferative diseases, comprising administering to a subject a compound of any of claims 1 to 5, or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, or a pharmaceutical composition of claim 6.


14. The method of claim 13, wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma and Kaposi's sarcoma.

15. Set (kit) consisting of separate packs of:

a) an effective amount of a compound according to any of claims 1 to 5 or a pharmaceutically acceptable salt, solvate, solvate of a salt, or prodrug thereof, or a pharmaceutical composition of claim 6, and


b) an effective amount of a further medicament active ingredient.

16. Process for the manufacture of a compound of Formula (I),
wherein X is N and Y is NH, and all other substituents have the meaning as defined for Formula (I) in claim 1, wherein a carboxylic acid ester of Formula (IV)




(IV),

is reacted with a compound of Formula (V)




(V),

to yield a compound of Formula (VI)



(VI).

which is finally converted into the carboxylic amide of Formula (I)



(I).

17. A compound of formula (I), (II) or (III), or a pharmaceutically acceptable salt, solvate, solvate of a salt or prodrug therof, or a pharmaceutical composition comprising the compound, or a use or method involving the compound or the pharmaceutical composition, or a kit comprising the compound or the pharmaceutical composition, or a process for the manufacture of a compound of Formula (I), substantially as herein described with reference to the accompanying Examples.